Mesenchymal stromal cell therapy in ischemic heart disease

References

• Kazi DS, Mark DB. The economics of heart failure. Heart Fail Clin. 2013;9:93–106.
   PubMed Web of Science ®Google Scholar
• Kastrup J. Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome? EPMA J. 2011;2:107–117.
   PubMedGoogle Scholar
• Fisher SA, Doree C, Brunskill SJ, et al. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS One. 2013;8:e64669.
   PubMed Web of Science ®Google Scholar
• Heeger CH, Jaquet K, Thiele H, et al. Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial. EuroIntervention. 2012;8:732–742.
   PubMed Web of Science ®Google Scholar
• Tendera M, Wojakowski W, Ruzyłło W, et al. REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34 + CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT). Trial Eur Heart J. 2009;30:1313–1321.
   PubMed Web of Science ®Google Scholar
• Lezaic L, Socan A, Poglajen G, et al. Intracoronary transplantation of CD34(+) cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. J Card Fail. 2015;21:145–152.
   PubMed Web of Science ®Google Scholar
• Gyöngyösi M, Wojakowski W, Lemarchand P, et al. ACCRUE Investigators. Meta-analysis of cell-based Cardiac studies (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346–1360.
   PubMed Web of Science ®Google Scholar
• Friis T, Haack-Sørensen M, Mathiasen AB, et al. Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand Cardiovasc J. 2011;45:161–168.
   PubMed Web of Science ®Google Scholar
• Haack-Sørensen M, Friis T, Mathiasen AB, et al. Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant. 2013;22:521–528.
   PubMed Web of Science ®Google Scholar
• Mathiasen AB, Haack-Sørensen M Jørgensen E., et al. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina-final 3-year follow-up. Int J Cardiol. 2013;170:246–251.
   PubMed Web of Science ®Google Scholar
• Qayyum AA, Haack-Sørensen M, Mathiasen AB, et al. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regen Med. 2012;7:421–428.
   PubMed Web of Science ®Google Scholar
• Mathiasen AB, Qayyum AA, Jørgensen E, et al. Bone-marrow derived mesenchymal stromal cell treatment in patients with severe ischemic heart failure: a randomised placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36:1744–1753.
   PubMed Web of Science ®Google Scholar
• Hass R, Kasper C, Böhm S, et al. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.
   PubMed Web of Science ®Google Scholar
• Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15:641–648.
   PubMed Web of Science ®Google Scholar
• Gnecchi M, Zhang Z, Ni A, et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204–1219.
   PubMed Web of Science ®Google Scholar
• Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med. 2012;18:128–134.
   PubMed Web of Science ®Google Scholar
• Melief SM, Zwaginga JJ, Fibbe WE, et al. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. 2013;2:455–463.
   PubMed Web of Science ®Google Scholar
• TiGenix web page [Internet]. [cited 2016 Sep 09]. Available from: www.tigenix.com.
   Google Scholar
• Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–2286.
   PubMed Web of Science ®Google Scholar
• Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369–2379.
   PubMed Web of Science ®Google Scholar
• Perin EC, Borow KM, Silva GV, et al. A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015;117:576–584.
   PubMed Web of Science ®Google Scholar
• De la Portilla F, Alba F, García-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313–323.
   PubMed Web of Science ®Google Scholar
• van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res. 2011;91:649–658.
   PubMed Web of Science ®Google Scholar
• Dixon JA, Gorman RC, Stroud RE, et al. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009;120:S220–S229.
   PubMed Web of Science ®Google Scholar
• Jansen Of Lorkeers SJ, Eding JE, Vesterinen HM, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2015;116:80–86.
   PubMed Web of Science ®Google Scholar
• Katritsis DG, Sotiropoulou PA, Karvouni E, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv. 2005;65:321–329.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang F, Ma W, et al. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther. 2010;28:380–385.
   PubMed Web of Science ®Google Scholar
• Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:539–540.
   PubMed Web of Science ®Google Scholar
• Mathiasen AB, Jørgensen E, Qayyum AA, et al. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). Am Heart J. 2012;164:285–291.
   PubMed Web of Science ®Google Scholar
• Juhl M, Tratwal J, Follin B, et al. Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue. Scand J Clin Lab Invest. 2016;76:93–104.
   PubMed Web of Science ®Google Scholar
• Chen S, Liu Z, Tian N, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18:552–556.
   PubMedGoogle Scholar
• Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med. 2007;10:467–473.
   PubMed Web of Science ®Google Scholar
• Katritsis DG, Sotiropoulou P, Giazitzoglou E, et al. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace. 2007;9:167–171.
   PubMed Web of Science ®Google Scholar
• Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011;108:792–796.
   PubMed Web of Science ®Google Scholar
• Lasala GP, Silva JA, Kusnick BA, et al. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovasc Revasc Med. 2011;12:29–34.
   PubMedGoogle Scholar